Germany's lower house of parliament approved a landmark healthcare reform bill aimed at stabilizing rising health insurance costs. The legislation targets drugmakers with higher mandatory rebates and caps hospital cost increases. Pharmaceutical giants like AstraZeneca are pushing back, warning the measures penalize innovation and could deter investment in Germany.
Germany's Bundestag passed a major healthcare reform bill on Friday designed to rein in soaring health insurance costs — a key pillar of Chancellor Friedrich Merz's broader economic revival plan. The bill now heads to the Bundesrat (the upper chamber), where approval is widely expected. Health Minister Nina Warken framed the reform as a responsible step toward financial stability, saying the goal is to limit future cost increases to the pace of overall economic growth rather than slash services across the board.
The reform targets the funding gap in Germany's statutory health insurance system — which covers most of the population and is financed through payroll contributions split between workers and employers — through a mix of cost controls. As contribution rates rise, businesses face higher labor costs and workers take home less pay, making this both an economic and political flashpoint.
Key Takeaways:
Why it matters: Pharmaceutical companies, including AstraZeneca, warn the measures punish innovation and could drive investment away from Germany — raising broader questions about how Europe's largest economy balances fiscal discipline with its role as a hub for life sciences.
